JP2022525429A5 - - Google Patents
Info
- Publication number
- JP2022525429A5 JP2022525429A5 JP2021557650A JP2021557650A JP2022525429A5 JP 2022525429 A5 JP2022525429 A5 JP 2022525429A5 JP 2021557650 A JP2021557650 A JP 2021557650A JP 2021557650 A JP2021557650 A JP 2021557650A JP 2022525429 A5 JP2022525429 A5 JP 2022525429A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- composition
- administered
- mol
- guide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025021006A JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825676P | 2019-03-28 | 2019-03-28 | |
| US201962825637P | 2019-03-28 | 2019-03-28 | |
| US62/825,676 | 2019-03-28 | ||
| US62/825,637 | 2019-03-28 | ||
| PCT/US2020/025533 WO2020198706A1 (en) | 2019-03-28 | 2020-03-27 | Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021006A Division JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525429A JP2022525429A (ja) | 2022-05-13 |
| JP2022525429A5 true JP2022525429A5 (https=) | 2023-12-15 |
| JP7636338B2 JP7636338B2 (ja) | 2025-02-26 |
Family
ID=70334147
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557650A Active JP7636338B2 (ja) | 2019-03-28 | 2020-03-27 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
| JP2025021006A Pending JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021006A Pending JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230035659A1 (https=) |
| EP (1) | EP3946285A1 (https=) |
| JP (2) | JP7636338B2 (https=) |
| KR (1) | KR20220004984A (https=) |
| CN (1) | CN113874004A (https=) |
| AU (1) | AU2020248337A1 (https=) |
| CA (1) | CA3134544A1 (https=) |
| CO (1) | CO2021014562A2 (https=) |
| MX (1) | MX2021011690A (https=) |
| WO (1) | WO2020198706A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| IL303506A (en) * | 2020-12-11 | 2023-08-01 | Intellia Therapeutics Inc | Polynucleotides, compositions, and methods for genome editing involving deamination |
| EP4322920A1 (en) * | 2021-04-17 | 2024-02-21 | Intellia Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2022246266A1 (en) * | 2021-05-21 | 2022-11-24 | Beam Therapeutics Inc. | Base editing of transthyretin gene |
| KR20240038705A (ko) * | 2021-06-22 | 2024-03-25 | 인텔리아 테라퓨틱스, 인크. | 간 유전자의 생체 내 편집 방법 |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| WO2024003805A1 (en) * | 2022-06-30 | 2024-01-04 | Geneditbio Limited | Methods and compositions for ttr gene editing and therapy using crispr system |
| CN120225668A (zh) * | 2023-10-25 | 2025-06-27 | 石药集团中奇制药技术（石家庄）有限公司 | 一种高效低脱靶的基因编辑工具 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| JPH10500310A (ja) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ |
| US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| AU2010223967B2 (en) * | 2009-03-12 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
| WO2014093655A2 (en) * | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| CN107879960B (zh) | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
| JP6712948B2 (ja) * | 2013-12-12 | 2020-06-24 | ザ・ブロード・インスティテュート・インコーポレイテッド | 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法 |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| CN120842296A (zh) | 2015-09-21 | 2025-10-28 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| WO2018007871A1 (en) * | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
| WO2018067447A1 (en) | 2016-10-03 | 2018-04-12 | Itellia Therapeutics, Inc. | Improved methods for identifying double strand break sites |
| WO2019067910A1 (en) * | 2017-09-29 | 2019-04-04 | Intellia Therapeutics, Inc. | POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION |
| US20230140670A1 (en) * | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| EP3688161A1 (en) * | 2017-09-29 | 2020-08-05 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating attr amyloidosis |
-
2020
- 2020-03-27 AU AU2020248337A patent/AU2020248337A1/en active Pending
- 2020-03-27 CA CA3134544A patent/CA3134544A1/en active Pending
- 2020-03-27 JP JP2021557650A patent/JP7636338B2/ja active Active
- 2020-03-27 EP EP20720676.4A patent/EP3946285A1/en active Pending
- 2020-03-27 MX MX2021011690A patent/MX2021011690A/es unknown
- 2020-03-27 WO PCT/US2020/025533 patent/WO2020198706A1/en not_active Ceased
- 2020-03-27 CN CN202080039394.5A patent/CN113874004A/zh active Pending
- 2020-03-27 KR KR1020217035012A patent/KR20220004984A/ko active Pending
-
2021
- 2021-09-27 US US17/486,758 patent/US20230035659A1/en not_active Abandoned
- 2021-10-28 CO CONC2021/0014562A patent/CO2021014562A2/es unknown
-
2025
- 2025-02-12 JP JP2025021006A patent/JP2025081416A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525429A5 (https=) | ||
| JP2022501040A5 (https=) | ||
| EP3305302B1 (en) | Compositions and methods for modulation of smn2 splicing in a subject | |
| CN102803284B (zh) | 用于miRNA抑制剂和模拟物的化学修饰基序 | |
| JP2023103244A5 (https=) | ||
| US10208309B2 (en) | Double-stranded oligo RNA targeted to amphiregulin and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases | |
| GB2612452A (en) | Base editing of PCSK9 and methods of using same for treatment of disease | |
| HRP20180093T1 (hr) | Pripravci i postupci za inhibiciju ekspresije transtiretina | |
| JP2023537943A5 (https=) | ||
| HK1246648A1 (en) | Compositions and methods for modulation of smn2 splicing in a subject | |
| CA2320965A1 (en) | Methods and compounds for the genetic treatment of hyperlipidemia | |
| EP3349730B1 (en) | Systems for nucleic acid expression in vivo | |
| JP2010532163A5 (https=) | ||
| JP2024512635A5 (https=) | ||
| JP2015518475A (ja) | 非アルコール性脂肪性肝炎の治療方法 | |
| JP2017510583A (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JP2024504266A (ja) | リジン分解関連障害の治療 | |
| KR20150006742A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
| JP2024543952A5 (https=) | ||
| JP2023541170A (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| WO2003043663A1 (fr) | Preparations inhibant le rejet dans la transplantation d'organe et son procede d'utilisation | |
| EP4192477A1 (en) | Treatment of skin diseases and disorders using inhibitors of kallikrein-related peptidases (klk) | |
| US20210338835A1 (en) | Methods for treating subjects suffering from acute myeloid leukemia with flt3 ligand-targeted mir-150 nanoparticles | |
| CN121538217B (zh) | 一种反义寡核苷酸Jag-i9 ASO及其应用 | |
| WO2022250050A1 (ja) | ｓｃｐＢＮＡ又はＡｍＮＡを含むヘテロ核酸 |